- Ab02674-23.0 Anti-GXM [18B7]
- Cryptococcus neoformans
- Rabbit IgG
- Ships in 4-5 weeks
- Ab02674-1.1 Anti-GXM [18B7]
- Cryptococcus neoformans
- Mouse IgG1
- In Stock
Recombinant monoclonal antibody to GXM. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 18B7.
Alternative Name(s) of Target: Glucuronoxylomannan; Cryptococcus neoformans capsular polysaccharide; CNPS
Immunogen: The original mouse version of this antibody was raised by infecting balb/c mice with C. neoformans and then immunizing them with glucuronoxylomannan-tetanus toxoid conjugate (GXM-TT).
Specificity: This antibody is specific for GXM from C.neoformans. GXM is a polysacharide experssed on the surface of c.neoformans.
Application Notes: To characterize the mouse version of this antibody an ELISA was performed on native and de-O-acetylated serotype A GMX using the mouse version of this antibody (Casadevall et al, 1992; pmid:1583327). Further immunofluorescence was performed on yeast cells using the mouse version of this antibody (Casadevell et al, 1998; pmid:9624491). Binding of the mouse version of this antibody to normal and C. neoformans-infected tissues was studied by immunohistochemistry (Casadevell et al, 1998; pmid:9624491). The murine macrophage-like cell line J774.16 was used to determine the ability of the mouse version of this antibody to opsonize C. neoformans (Casadevell et al, 1998; pmid:9624491). The effect of the murine version of this antibody on human PMN phagocytosis of C. neoformans was measured by a flow cytometry (Casadevell et al, 1998; pmid:9624491). C3 binding studies were done with formalin-killed cells of strain 388. The kinetics were studied both in the presence and absence of the murine version of this antibody (Casadevell et al, 1998; pmid:9624491). The ability of the mouse version of this antibody to reduce serum antigen in A/J mice was tested (Casadevell et al, 1998; pmid:9624491). The mouse version of this antibody has shown promise in a phase 1 trial testing patients with treated cryptococcal meningitis (Larsen et al, 2005; pmid:15728888). While developing a diagnostic test for Cryptococcal capsular antigens. The mouse version of this antibody was used for ELISA to test cross-reactivity with capsid antigens of other yeast species (Sathongdejwisit et al, 2021; pmid:33922698).
Antibody first published in:
Casadevall et al. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection J Infect Dis. 1992 Jun;165(6):1086-93. PMID:1583327
Note on publication: The antibody responses of BALB/c mice to serotype A Cryptococcus neoformans capsular polysaccharide (CNPS) were compared after cryptococcal infection and immunization with a serotype A glucuronoxylomannan-tetanus toxoid conjugate.